|Bid||0.7800 x 1200|
|Ask||0.7858 x 1200|
|Day's range||0.7513 - 0.8200|
|52-week range||0.4500 - 2.3400|
|Beta (5Y monthly)||1.28|
|PE ratio (TTM)||N/A|
|Earnings date||22 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Kennette Phillips, site manager for the first bitcoin mining operation on Navajo land, joins Yahoo Finance to discuss the project.
Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.
SAN DIEGO, July 19, 2021--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis" or the "Company") today announced that based on the Inspector of Election’s certified results from the Company’s 2021 Annual Meeting of Stockholders (the "Annual Meeting"), each of the Company’s nominees – Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams – have been re-elected to the Board of Directors (the "Board"). According to the Inspector of Election’